Warum explodiert Affymetrix gerade???? - 500 Beiträge pro Seite
eröffnet am 02.11.00 15:18:13 von
neuester Beitrag 03.11.00 00:07:43 von
neuester Beitrag 03.11.00 00:07:43 von
Beiträge: 11
ID: 288.600
ID: 288.600
Aufrufe heute: 0
Gesamt: 1.444
Gesamt: 1.444
Aktive User: 0
ISIN: US00826T1088 · WKN: 901198
14,010
USD
0,00 %
0,000 USD
Letzter Kurs 01.04.16 Nasdaq
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 7,4600 | +45,99 | |
| 0,5922 | +44,44 | |
| 11,870 | +43,01 | |
| 0,7000 | +36,69 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,6700 | -12,17 | |
| 10,110 | -13,44 | |
| 7,6100 | -17,20 | |
| 1,6100 | -18,27 | |
| 2,1200 | -21,77 |
Feedback
Warum ist meine alte Affymetrix gerade am Explodieren, habe ich was verpasst??
Bin seit 75 EUR dabei.
grüße
Bin seit 75 EUR dabei.
grüße
Sie explodiert immer noch (in 40 min 30%)
Weiß denn keiner warum?
Weiß denn keiner warum?
U.K. Court of Appeal Rules Affymetrix Owns OGT Patent License -- 7:15 AM EDT
SANTA CLARA, Calif., Nov 2, 2000 /PRNewswire via COMTEX/ -- Affymetrix, Inc.
(Nasdaq: AFFX) said that the U.K. Court of Appeal unanimously held today that
Affymetrix` purchase of the Beckman Coulter microarray business transferred a
license to the "Southern Patents." The decision reversed an April 2000 finding
of the U.K. High Court in litigation brought against Affymetrix by Oxford Gene
Technology Limited (OGT).
Specifically, Lord Justice Aldous, who delivered the leading judgment, concluded
"Affymetrix has a license as a result of the purchase of the business of
Beckman."
Vern Norviel, Senior Vice President and General Counsel of Affymetrix,
commented, "We welcome the decision by the Court of Appeal and will continue our
mission of providing GeneChip(R) products and other enabling genetic analysis
tools to scientists working to understand the human genome and help cure
disease."
"In light of this decision, Affymetrix now looks forward to a determination in
the U.S. District Court in Delaware that its current products are not covered by
any valid OGT claim, in which case Affymetrix may no longer need to pay
royalties to OGT," said Phil McGarrigle, Chief Intellectual Property Counsel of
Affymetrix. "Furthermore, our freedom to operate under OGT`s patents is now
clear and unequivocal, if we should need it."
Affymetrix is a leader in developing and commercializing systems to acquire,
analyze and manage complex genetic information in order to improve the quality
of life. The Company`s GeneChip system consists of disposable DNA probe arrays
containing gene sequences on a chip, reagents for use with the probe arrays, a
scanner, and other instruments to process the probe arrays and software to
analyze and manage genetic information. The Company`s spotted array system
enables individual researchers to create and analyze custom microarrays on an
easy-to-use, cost efficient platform. Additional information on Affymetrix and
GeneChip technology can be found at www.affymetrix.com.
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the Securities
Exchange Act as amended, including statements regarding Affymetrix`
"expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such
statements are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected, including, but
not limited to, uncertainties relating to technological approaches, product
development, manufacturing, market acceptance, personnel retention, equity
dilution, uncertainties related to the ability to realize benefits from
acquisitions, uncertainties related to cost and pricing of Affymetrix products,
dependence on collaborative partners, uncertainties relating to sole source
suppliers, uncertainties relating to FDA and other regulatory approvals,
competition, risks relating to intellectual property of others and the
uncertainties of patent protection and litigation. These and other risk factors
are discussed in Affymetrix` Annual Report on Form 10-K for the year ended
December 31, 1999 and other SEC reports, including its Quarterly Reports on Form
10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in Affymetrix`
expectations with regard thereto or any change in events, conditions, or
circumstances on which any such statements are based. Affymetrix, GeneChip and
the Affymetrix logo are registered trademarks used by Affymetrix, Inc.
SOURCE Affymetrix, Inc.
CONTACT: Edward M. Hurwitz, Vice President and Chief Financial Officer,
408-731-5000, or Anne Bowdidge, Director of Investor Relations, 408-731-5925,
both of Affymetrix, Inc.
URL: http://www.affymetrix.com
http://www.prnewswire.com
(C) 2000 PR Newswire. All rights reserved.
SANTA CLARA, Calif., Nov 2, 2000 /PRNewswire via COMTEX/ -- Affymetrix, Inc.
(Nasdaq: AFFX) said that the U.K. Court of Appeal unanimously held today that
Affymetrix` purchase of the Beckman Coulter microarray business transferred a
license to the "Southern Patents." The decision reversed an April 2000 finding
of the U.K. High Court in litigation brought against Affymetrix by Oxford Gene
Technology Limited (OGT).
Specifically, Lord Justice Aldous, who delivered the leading judgment, concluded
"Affymetrix has a license as a result of the purchase of the business of
Beckman."
Vern Norviel, Senior Vice President and General Counsel of Affymetrix,
commented, "We welcome the decision by the Court of Appeal and will continue our
mission of providing GeneChip(R) products and other enabling genetic analysis
tools to scientists working to understand the human genome and help cure
disease."
"In light of this decision, Affymetrix now looks forward to a determination in
the U.S. District Court in Delaware that its current products are not covered by
any valid OGT claim, in which case Affymetrix may no longer need to pay
royalties to OGT," said Phil McGarrigle, Chief Intellectual Property Counsel of
Affymetrix. "Furthermore, our freedom to operate under OGT`s patents is now
clear and unequivocal, if we should need it."
Affymetrix is a leader in developing and commercializing systems to acquire,
analyze and manage complex genetic information in order to improve the quality
of life. The Company`s GeneChip system consists of disposable DNA probe arrays
containing gene sequences on a chip, reagents for use with the probe arrays, a
scanner, and other instruments to process the probe arrays and software to
analyze and manage genetic information. The Company`s spotted array system
enables individual researchers to create and analyze custom microarrays on an
easy-to-use, cost efficient platform. Additional information on Affymetrix and
GeneChip technology can be found at www.affymetrix.com.
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the Securities
Exchange Act as amended, including statements regarding Affymetrix`
"expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such
statements are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected, including, but
not limited to, uncertainties relating to technological approaches, product
development, manufacturing, market acceptance, personnel retention, equity
dilution, uncertainties related to the ability to realize benefits from
acquisitions, uncertainties related to cost and pricing of Affymetrix products,
dependence on collaborative partners, uncertainties relating to sole source
suppliers, uncertainties relating to FDA and other regulatory approvals,
competition, risks relating to intellectual property of others and the
uncertainties of patent protection and litigation. These and other risk factors
are discussed in Affymetrix` Annual Report on Form 10-K for the year ended
December 31, 1999 and other SEC reports, including its Quarterly Reports on Form
10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in Affymetrix`
expectations with regard thereto or any change in events, conditions, or
circumstances on which any such statements are based. Affymetrix, GeneChip and
the Affymetrix logo are registered trademarks used by Affymetrix, Inc.
SOURCE Affymetrix, Inc.
CONTACT: Edward M. Hurwitz, Vice President and Chief Financial Officer,
408-731-5000, or Anne Bowdidge, Director of Investor Relations, 408-731-5925,
both of Affymetrix, Inc.
URL: http://www.affymetrix.com
http://www.prnewswire.com
(C) 2000 PR Newswire. All rights reserved.
Affx. hat nach eigenen Angaben den Rechtstreit gegen "Oxford" gewonnen.
Eine offizielle Meldung habe ich noch nicht finden können, werde mich aber jetzt daran machen.
Eine offizielle Meldung habe ich noch nicht finden können, werde mich aber jetzt daran machen.
Thursday November 2, 7:04 am Eastern Time
Press Release
SOURCE: Affymetrix, Inc.
U.K. Court of Appeal Rules Affymetrix Owns OGT
Patent License
SANTA CLARA, Calif., Nov. 2 /PRNewswire/ -- Affymetrix, Inc. (Nasdaq: AFFX - news) said that the U.K. Court of Appeal
unanimously held today that Affymetrix` purchase of the Beckman Coulter microarray business transferred a license to the
``Southern Patents.`` The decision reversed an April 2000 finding of the U.K. High Court in litigation brought against Affymetrix by
Oxford Gene Technology Limited (OGT).
Specifically, Lord Justice Aldous, who delivered the leading judgment, concluded ``Affymetrix has a license as a result of the
purchase of the business of Beckman.``
Vern Norviel, Senior Vice President and General Counsel of Affymetrix, commented, ``We welcome the decision by the Court of
Appeal and will continue our mission of providing GeneChip® products and other enabling genetic analysis tools to scientists
working to understand the human genome and help cure disease.``
``In light of this decision, Affymetrix now looks forward to a determination in the U.S. District Court in Delaware that its current
products are not covered by any valid OGT claim, in which case Affymetrix may no longer need to pay royalties to OGT,`` said
Phil McGarrigle, Chief Intellectual Property Counsel of Affymetrix. ``Furthermore, our freedom to operate under OGT`s patents is
now clear and unequivocal, if we should need it.``
Affymetrix is a leader in developing and commercializing systems to acquire, analyze and manage complex genetic information in
order to improve the quality of life. The Company`s GeneChip system consists of disposable DNA probe arrays containing gene
sequences on a chip, reagents for use with the probe arrays, a scanner, and other instruments to process the probe arrays and
software to analyze and manage genetic information. The Company`s spotted array system enables individual researchers to create
and analyze custom microarrays on an easy-to-use, cost efficient platform. Additional information on Affymetrix and GeneChip
technology can be found at www.affymetrix.com.
All statements in this press release that are not historical are ``forward-looking statements`` within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements regarding Affymetrix` ``expectations,`` ``beliefs,`` ``hopes,``
``intentions,`` ``strategies`` or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ
materially for Affymetrix from those projected, including, but not limited to, uncertainties relating to technological approaches,
product development, manufacturing, market acceptance, personnel retention, equity dilution, uncertainties related to the ability to
realize benefits from acquisitions, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative
partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition,
risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors
are discussed in Affymetrix` Annual Report on Form 10-K for the year ended December 31, 1999 and other SEC reports,
including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change
in Affymetrix` expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements
are based. Affymetrix, GeneChip and the Affymetrix logo are registered trademarks used by Affymetrix, Inc.
SOURCE: Affymetrix, Inc.
Email this story - Most-emailed articles - Most-viewed articles
Press Release
SOURCE: Affymetrix, Inc.
U.K. Court of Appeal Rules Affymetrix Owns OGT
Patent License
SANTA CLARA, Calif., Nov. 2 /PRNewswire/ -- Affymetrix, Inc. (Nasdaq: AFFX - news) said that the U.K. Court of Appeal
unanimously held today that Affymetrix` purchase of the Beckman Coulter microarray business transferred a license to the
``Southern Patents.`` The decision reversed an April 2000 finding of the U.K. High Court in litigation brought against Affymetrix by
Oxford Gene Technology Limited (OGT).
Specifically, Lord Justice Aldous, who delivered the leading judgment, concluded ``Affymetrix has a license as a result of the
purchase of the business of Beckman.``
Vern Norviel, Senior Vice President and General Counsel of Affymetrix, commented, ``We welcome the decision by the Court of
Appeal and will continue our mission of providing GeneChip® products and other enabling genetic analysis tools to scientists
working to understand the human genome and help cure disease.``
``In light of this decision, Affymetrix now looks forward to a determination in the U.S. District Court in Delaware that its current
products are not covered by any valid OGT claim, in which case Affymetrix may no longer need to pay royalties to OGT,`` said
Phil McGarrigle, Chief Intellectual Property Counsel of Affymetrix. ``Furthermore, our freedom to operate under OGT`s patents is
now clear and unequivocal, if we should need it.``
Affymetrix is a leader in developing and commercializing systems to acquire, analyze and manage complex genetic information in
order to improve the quality of life. The Company`s GeneChip system consists of disposable DNA probe arrays containing gene
sequences on a chip, reagents for use with the probe arrays, a scanner, and other instruments to process the probe arrays and
software to analyze and manage genetic information. The Company`s spotted array system enables individual researchers to create
and analyze custom microarrays on an easy-to-use, cost efficient platform. Additional information on Affymetrix and GeneChip
technology can be found at www.affymetrix.com.
All statements in this press release that are not historical are ``forward-looking statements`` within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements regarding Affymetrix` ``expectations,`` ``beliefs,`` ``hopes,``
``intentions,`` ``strategies`` or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ
materially for Affymetrix from those projected, including, but not limited to, uncertainties relating to technological approaches,
product development, manufacturing, market acceptance, personnel retention, equity dilution, uncertainties related to the ability to
realize benefits from acquisitions, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative
partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition,
risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors
are discussed in Affymetrix` Annual Report on Form 10-K for the year ended December 31, 1999 and other SEC reports,
including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change
in Affymetrix` expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements
are based. Affymetrix, GeneChip and the Affymetrix logo are registered trademarks used by Affymetrix, Inc.
SOURCE: Affymetrix, Inc.
Email this story - Most-emailed articles - Most-viewed articles
Trading Spotlight
Wird Affymetrix nun mein ERSTER RICHTIGER VEDOPPLER 
?!?
cu tschaki
?!?cu tschaki
Hi tschaki
Ich wünsche es Dir
Gruß
SanTau
Ich wünsche es Dir
Gruß
SanTau
Hi
Affymetrix mit hartem Widerstand bei 80$ wurde heute schon intradaymäßig geteste, also freunde bei 80$ kurzfristig verkaufen und warten bis der Kurs wieder darunter fällt und wieder zuschlagen.
Habe es heute leider knapp verpaßt zu verkaufen, jetzt 17 uhr 47 min liegt er bei 74$
Chiou
Affymetrix mit hartem Widerstand bei 80$ wurde heute schon intradaymäßig geteste, also freunde bei 80$ kurzfristig verkaufen und warten bis der Kurs wieder darunter fällt und wieder zuschlagen.
Habe es heute leider knapp verpaßt zu verkaufen, jetzt 17 uhr 47 min liegt er bei 74$
Chiou
HI
The company showed a gain of 17 points today as a result of a decision reversing an April 2000 finding of the U.K. High Court. Litigation had been brought against Affymetrix by Oxford Gene Technology Limited (OGT). The U.K. Court of Appeals ruled that Affymetrix owns OGT Patent License. In light of this decision, Affymetrix now looks forward to a determination in the U.S. Court in Delaware that its current products are not covered by any valid OGT claim. As a result, Affymetrix may no longer need to pay royalties to OGT making this a stock to watch.
JAja guter court of appeals (Berufungsgericht) könnte jetzt ein Signal sein auch andere Lizenzklagen zugewinnen.
Traue mich gar nicht darüber nachzudenken was das für "Kurserholungen" binnen kürzester Zeit bringen wird, also als nächstes sind die amerikanischen Gerichte dran um diese unselligen Patentstreitereien zu lösen und zwar im Sinne von Affymetrix
Guten Abend noch
The company showed a gain of 17 points today as a result of a decision reversing an April 2000 finding of the U.K. High Court. Litigation had been brought against Affymetrix by Oxford Gene Technology Limited (OGT). The U.K. Court of Appeals ruled that Affymetrix owns OGT Patent License. In light of this decision, Affymetrix now looks forward to a determination in the U.S. Court in Delaware that its current products are not covered by any valid OGT claim. As a result, Affymetrix may no longer need to pay royalties to OGT making this a stock to watch.
JAja guter court of appeals (Berufungsgericht) könnte jetzt ein Signal sein auch andere Lizenzklagen zugewinnen.
Traue mich gar nicht darüber nachzudenken was das für "Kurserholungen" binnen kürzester Zeit bringen wird, also als nächstes sind die amerikanischen Gerichte dran um diese unselligen Patentstreitereien zu lösen und zwar im Sinne von Affymetrix
Guten Abend noch
Hallo, hier die Meldung:
Das britische Berufungsgericht sprach sich im Rechtsstreit zwischen dem englischen Bitoechunternehmen Oxford Gene Technology (OGT) und dem amerikanischen Genchipspezialisten Affymetrix (Nasdaq: AFFX) einstimmig für Affymetrix aus. Damit ist die Übertragung der Lizenzen an den sogenannten „Southern Patenten“ auf Affymetrix auch gesetzlich gefestigt.
Durch die Übernahme des Datenbankgeschäftes von Beckman Coulter behauptete Affymetrix, die Lizenzen an den „Southern Patenten“ mit erworben zu haben. OGT vertrat die Position, dass Affymetrixs GeneChip-Technologie diese Patente verletze und Affymetrix eben keine Rechte auf diese Patente hätte. Das Gericht entschied nun, dass die Lizenzen auf die Patente mit dem Kauf des Beckman Coulter Bereichs auf Affymetrix übergegangen seien und somit keine Patentverletzung vorliege.
Diese Entscheidung machte eine frühere Rechtssprechung des Hohen Gerichtshofs von Großbritannien wieder rückgängig. Wir berichteten bereits über mögliche Schadensersatzforderungen historie und die Berufungsschritte von Affymetrix historie.
In den USA läuft aktuell noch ein Prozess zwischen den beiden Unternehmen, wobei Affymetrix nach der Entscheidung in Großbritannien sehr zuversichtlich ist, dass auch in Amerika der Rechtsstreit gewonnen werde. Damit müsste Affymetrix keine Lizenzzahlungen an OGT leisten.
Die Aktien explodieren heute förmlich. In der Spitze notiert die Aktie mit einem Plus von über 30 Prozent auf einem Tageshoch von 81 3/8 Dollar.
Quelle:
http://cdinf2.comdirect.de:9004/de/detail/_pages/news/articl…
Das britische Berufungsgericht sprach sich im Rechtsstreit zwischen dem englischen Bitoechunternehmen Oxford Gene Technology (OGT) und dem amerikanischen Genchipspezialisten Affymetrix (Nasdaq: AFFX) einstimmig für Affymetrix aus. Damit ist die Übertragung der Lizenzen an den sogenannten „Southern Patenten“ auf Affymetrix auch gesetzlich gefestigt.
Durch die Übernahme des Datenbankgeschäftes von Beckman Coulter behauptete Affymetrix, die Lizenzen an den „Southern Patenten“ mit erworben zu haben. OGT vertrat die Position, dass Affymetrixs GeneChip-Technologie diese Patente verletze und Affymetrix eben keine Rechte auf diese Patente hätte. Das Gericht entschied nun, dass die Lizenzen auf die Patente mit dem Kauf des Beckman Coulter Bereichs auf Affymetrix übergegangen seien und somit keine Patentverletzung vorliege.
Diese Entscheidung machte eine frühere Rechtssprechung des Hohen Gerichtshofs von Großbritannien wieder rückgängig. Wir berichteten bereits über mögliche Schadensersatzforderungen historie und die Berufungsschritte von Affymetrix historie.
In den USA läuft aktuell noch ein Prozess zwischen den beiden Unternehmen, wobei Affymetrix nach der Entscheidung in Großbritannien sehr zuversichtlich ist, dass auch in Amerika der Rechtsstreit gewonnen werde. Damit müsste Affymetrix keine Lizenzzahlungen an OGT leisten.
Die Aktien explodieren heute förmlich. In der Spitze notiert die Aktie mit einem Plus von über 30 Prozent auf einem Tageshoch von 81 3/8 Dollar.
Quelle:
http://cdinf2.comdirect.de:9004/de/detail/_pages/news/articl…
Suuupppper
Affymetrics +34%
Jetzt gehts zügig auf 100$ und das ist erst der Anfang!!
Saludos de Lima
Affymetrics +34%
Jetzt gehts zügig auf 100$ und das ist erst der Anfang!!
Saludos de Lima
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,73 | |
| -5,17 | |
| +6,46 | |
| +3,18 | |
| -0,26 | |
| +1,11 | |
| -0,06 | |
| -0,07 | |
| -0,24 | |
| +1,38 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 215 | ||
| 90 | ||
| 76 | ||
| 58 | ||
| 54 | ||
| 36 | ||
| 34 | ||
| 29 | ||
| 27 | ||
| 25 |
